NKTR: Nektar Therapeutics Stocks News on October 8, 2025

Here's Why Nektar Therapeutics Stock Rocketed 90.6% Higher in September

NKTR

Motley Fool

3 days ago

Here's Why Nektar Therapeutics Stock Rocketed 90.6% Higher in September

NKTR

MT Newswires

15 days ago

B. Riley Boosts Price Target on Nektar Therapeutics to $105 From $85, Keeps Buy Rating

These 2 Healthcare Stocks Are Up Over 100% in a Month. Can They Keep Climbing?

NKTR

Motley Fool

16 days ago

These 2 Healthcare Stocks Are Up Over 100% in a Month. Can They Keep Climbing?

How Recent Breakthroughs Are Changing the Nektar Therapeutics Investment Story

NKTR

Simply Wall St.

18 days ago

How Recent Breakthroughs Are Changing the Nektar Therapeutics Investment Story

NKTR

Zacks

a month ago

NKTR Shares Surge 38.2% in a Week: Here's What You Should Know

Why Nektar Therapeutics Rippled Higher This Week

NKTR

Motley Fool

a month ago

Why Nektar Therapeutics Rippled Higher This Week

NKTR

MT Newswires

a month ago

Sector Update: Health Care Stocks Rise Late Afternoon

NKTR

MT Newswires

a month ago

Sector Update: Health Care Stocks Rise Thursday Afternoon

NKTR

MT Newswires

a month ago

Nektar Therapeutics Shares Jump as Sanofi's Eczema Drug Results Miss Expectations in Study

Why Nektar Therapeutics Stock Was Red-Hot Today

NKTR

Motley Fool

3 months ago

Why Nektar Therapeutics Stock Was Red-Hot Today

Wainwright sets over $100 target for Nektar on ‘paradigm-shifting’ data

NKTR

TipRanks

3 months ago

Wainwright sets over $100 target for Nektar on ‘paradigm-shifting’ data

NKTR

Zacks

3 months ago

NKTR Stock Soars as Lead Drug Meets Goal in Atopic Dermatitis Study

Nektar Therapeutics Launches After Unearthing 'A New Biology' In Eczema Treatment

NKTR

Investor's Business Daily

3 months ago

Nektar Therapeutics Launches After Unearthing 'A New Biology' In Eczema Treatment

NKTR

MT Newswires

3 months ago

Sector Update: Health Care Stocks Advance Late Afternoon

NKTR

MT Newswires

3 months ago

BTIG Raises Nektar Therapeutics' Price Target to $100 From $60, Buy Rating Maintained

NKTR

MT Newswires

3 months ago

Sector Update: Health Care Stocks Higher in Afternoon Trading

NKTR

MT Newswires

3 months ago

Sector Update: Health Care Stocks Edge Higher Premarket Tuesday

NKTR

MT Newswires

3 months ago

Nektar Therapeutics Says Phase 2b Study of Rezpegaldesleukin Meets Primary Endpoint in Patients With Atopic Dermatitis -- Shares Surge

NKTR

MT Newswires

3 months ago

REZOLVE-AD Phase 2b Study of Rezpegaldesleukin Meets Primary and Key Secondary Endpoints in Patients with Moderate-to-Severe Atopic Dermatitis

Nektar to Announce Top-line Data from the 16-Week Induction Period in REZOLVE-AD Phase 2b Study of Rezpegaldesleukin, a Regulatory T-cell Proliferator, in Atopic Dermatitis on June 24, 2025

NKTR

PR Newswire

3 months ago

Nektar to Announce Top-line Data from the 16-Week Induction Period in REZOLVE-AD Phase 2b Study of Rezpegaldesleukin, a Regulatory T-cell Proliferator, in Atopic Dermatitis on June 24, 2025

NKTR

Simply Wall St.

5 months ago

Nektar Therapeutics (NASDAQ:NKTR) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference

NKTR

PR Newswire

5 months ago

Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference

NKTR

Simply Wall St.

5 months ago

Time To Worry? Analysts Are Downgrading Their Nektar Therapeutics (NASDAQ:NKTR) Outlook

Nektar Therapeutics First Quarter 2025 Earnings: Misses Expectations

NKTR

Simply Wall St.

5 months ago

Nektar Therapeutics First Quarter 2025 Earnings: Misses Expectations

NKTR

Thomson Reuters StreetEvents

5 months ago

Q1 2025 Nektar Therapeutics Earnings Call

Nektar Q1 Loss Wider Than Expected, Revenues Fall Y/Y, Stock Down

NKTR

Zacks

5 months ago

Nektar Q1 Loss Wider Than Expected, Revenues Fall Y/Y, Stock Down

NKTR

GuruFocus.com

5 months ago

Nektar Therapeutics (NKTR) Q1 2025 Earnings Call Highlights: Advancements in Immunology and ...

NKTR

Zacks

5 months ago

Nektar Therapeutics (NKTR) Reports Q1 Loss, Lags Revenue Estimates

NKTR

Associated Press Finance

5 months ago

Nektar Therapeutics Reports First Quarter 2025 Financial Results

Nektar to Announce Financial Results for the First Quarter on Thursday, May 8, 2025, After Close of U.S.-Based Financial Markets

NKTR

PR Newswire

5 months ago

Nektar to Announce Financial Results for the First Quarter on Thursday, May 8, 2025, After Close of U.S.-Based Financial Markets

NKTR

Zacks

5 months ago

Will Nektar Therapeutics (NKTR) Report Negative Q1 Earnings? What You Should Know

Jefferies Upgrades Nektar Therapeutics to Buy, Doubles Price Target to $2.00

NKTR

GuruFocus.com

6 months ago

Jefferies Upgrades Nektar Therapeutics to Buy, Doubles Price Target to $2.00

NKTR

MT Newswires

6 months ago

Nektar Therapeutics Shares Rise After Upgrade From Jefferies

NKTR

Zacks

6 months ago

Why Is Nektar (NKTR) Down 38.8% Since Last Earnings Report?

NKTR

MT Newswires

6 months ago

Jefferies Upgrades Nektar Therapeutics to Buy From Hold, Adjusts Price Target to $2 From $1

NKTR

MT Newswires

6 months ago

Nektar Therapeutics Files $300 Million Mixed Shelf

NKTR

Insider Monkey

7 months ago

Nektar Therapeutics (NKTR): Among Stocks Wall Street Is Calling Bullish Amid Market Turmoil

Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

NKTR

PR Newswire

7 months ago

Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

NKTR

MT Newswires

7 months ago

Nektar Therapeutics Shares Rise After Upgrade From Oppenheimer

NKTR

Zacks

7 months ago

Nektar Therapeutics (NKTR) Q4 Earnings Miss Estimates (Revised)

NKTR

MT Newswires

7 months ago

Oppenheimer Upgrades Nektar Therapeutics to Outperform From Market Perform, Price Target is $6

Nektar Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

NKTR

Simply Wall St.

7 months ago

Nektar Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

Nektar Q4 Loss Wider Than Expected, Pipeline in Focus, Stock Up

NKTR

Zacks

7 months ago

Nektar Q4 Loss Wider Than Expected, Pipeline in Focus, Stock Up

NKTR

Thomson Reuters StreetEvents

7 months ago

Q4 2024 Nektar Therapeutics Earnings Call

NKTR

GuruFocus.com

7 months ago

Nektar Therapeutics (NKTR) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial ...

NKTR

Zacks

7 months ago

Nektar (NKTR) Reports Q4 Earnings: What Key Metrics Have to Say

NKTR

Zacks

7 months ago

Nektar Therapeutics (NKTR) Q4 Earnings Beat Estimates

NKTR

Associated Press Finance

7 months ago

Assertio (ASRT) Reports Q4 Loss, Tops Revenue Estimates

Nektar Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

NKTR

PR Newswire

7 months ago

Nektar Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2024 on Wednesday, March 12, 2025, After Close of U.S.-Based Financial Markets

NKTR

PR Newswire

7 months ago

Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2024 on Wednesday, March 12, 2025, After Close of U.S.-Based Financial Markets

Nektar completes enrolment in trial of rezpegaldesleukin for alopecia areata

NKTR

Clinical Trials Arena

7 months ago

Nektar completes enrolment in trial of rezpegaldesleukin for alopecia areata

Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AA Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Severe-to-Very Severe Alopecia Areata

NKTR

PR Newswire

7 months ago

Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AA Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Severe-to-Very Severe Alopecia Areata

NKTR

MT Newswires

7 months ago

Nektar Therapeutics Partners With TrialNet to Test Rezpegaldesleukin in Type 1 Diabetes

Nektar Announces Clinical Trial Agreement to Evaluate Rezpegaldesleukin in Patients with New Onset Type 1 Diabetes Mellitus

NKTR

PR Newswire

7 months ago

Nektar Announces Clinical Trial Agreement to Evaluate Rezpegaldesleukin in Patients with New Onset Type 1 Diabetes Mellitus

Nektar Therapeutics to Host Virtual Investor & Analyst Event with Type 1 Diabetes Experts on February 24th

NKTR

PR Newswire

7 months ago

Nektar Therapeutics to Host Virtual Investor & Analyst Event with Type 1 Diabetes Experts on February 24th

NKTR

MT Newswires

8 months ago

Nektar Says FDA Grants Fast-Track Designation to Atopic Dermatitis Treatment

Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Moderate-to-Severe Atopic Dermatitis

NKTR

PR Newswire

8 months ago

Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Moderate-to-Severe Atopic Dermatitis

NKTR

Zacks

8 months ago

Down -38.51% in 4 Weeks, Here's Why Nektar (NKTR) Looks Ripe for a Turnaround

NKTR

Zacks

8 months ago

Zacks Industry Outlook Highlights Corcept, Amneal, Dyne, Nektar and Cardiol

NKTR

Zacks

8 months ago

Nektar (NKTR) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

5 Small Drug Stocks to Add to Your Kitty in the Trump 2.0 Era

NKTR

Zacks

8 months ago

5 Small Drug Stocks to Add to Your Kitty in the Trump 2.0 Era

MediWound (MDWD) Surges 8.5%: Is This an Indication of Further Gains?

NKTR

Zacks

8 months ago

MediWound (MDWD) Surges 8.5%: Is This an Indication of Further Gains?

Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AD Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Moderate-to-Severe Atopic Dermatitis

NKTR

PR Newswire

9 months ago

Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AD Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Moderate-to-Severe Atopic Dermatitis

NKTR

MT Newswires

9 months ago

B. Riley Starts Nektar Therapeutics With Buy Rating, $4 Price Target

NKTR

Insider Monkey

9 months ago

Why Nektar Therapeutics (NKTR) Is Among the Best Penny Stocks to Invest In According to Media?

NKTR

Simply Wall St.

9 months ago

Institutional investors have a lot riding on Nektar Therapeutics (NASDAQ:NKTR) with 68% ownership

NKTR

MT Newswires

10 months ago

HC Wainwright Initiates Nektar Therapeutics at Buy With $6.50 Price Target

$Nektar Therapeutics Announces NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients with Relapsed or Refractory Large B-cell Lymphoma at the 66th Annual ASH Meeting$

NKTR

PR Newswire

10 months ago

Nektar Therapeutics Announces NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients with Relapsed or Refractory Large B-cell Lymphoma at the 66th Annual ASH Meeting

NKTR

PR Newswire

a year ago

Nektar Therapeutics Presents First Preclinical Data from Novel CSF-1 Program, NKTR-422, at 2024 American College of Rheumatology (ACR) Convergence

NKTR

Simply Wall St.

a year ago

Nektar Therapeutics (NASDAQ:NKTR) Just Reported And Analysts Have Been Lifting Their Price Targets

Nektar Therapeutics Third Quarter 2024 Earnings: Beats Expectations

NKTR

Simply Wall St.

a year ago

Nektar Therapeutics Third Quarter 2024 Earnings: Beats Expectations

Nektar Q3 Loss Narrower Than Expected, Pipeline Development in Focus

NKTR

Zacks

a year ago

Nektar Q3 Loss Narrower Than Expected, Pipeline Development in Focus

NKTR

GuruFocus.com

a year ago

Nektar Therapeutics (NKTR) Q3 2024 Earnings Call Highlights: Strategic Moves and Financial Outlook

NKTR

Zacks

a year ago

Nektar Therapeutics (NKTR) Reports Q3 Loss, Tops Revenue Estimates

NKTR

Associated Press Finance

a year ago

Nektar: Q3 Earnings Snapshot

Nektar Therapeutics Reports Third Quarter 2024 Financial Results

NKTR

PR Newswire

a year ago

Nektar Therapeutics Reports Third Quarter 2024 Financial Results

NKTR

MT Newswires

a year ago

Nektar Therapeutics Says NKTR-255 Boosts Immune Recovery After Radiation Therapy

NKTR

PR Newswire

a year ago

Nektar and Collaborators Present Late-breaking Results from Phase 2 Study of NKTR-255 for the Treatment of Radiation Induced Lymphopenia in Locally Advanced Non-Small Cell Lung Cancer Patients at Society for Immunotherapy of Cancer (SITC) Annual Meeting

Nektar Therapeutics to Participate in Upcoming Investor Conferences

NKTR

PR Newswire

a year ago

Nektar Therapeutics to Participate in Upcoming Investor Conferences

Nektar Therapeutics to sell Alabama facility to Ampersand

NKTR

Pharmaceutical Technology

a year ago

Nektar Therapeutics to sell Alabama facility to Ampersand

Eczema Drug Developer Nektar Gains Analyst Confidence With 400% Upside Potential

NKTR

Benzinga

a year ago

Eczema Drug Developer Nektar Gains Analyst Confidence With 400% Upside Potential

NKTR

MT Newswires

a year ago

Nektar Therapeutics Shares Rise After Deal to Sell Alabama Facility, PEGylation Business for $90 Million

Nektar Announces Definitive Agreement with Ampersand Capital Partners to Sell Its Commercial PEGylation Reagent Manufacturing Business in Alabama

NKTR

PR Newswire

a year ago

Nektar Announces Definitive Agreement with Ampersand Capital Partners to Sell Its Commercial PEGylation Reagent Manufacturing Business in Alabama

Nektar to Announce Financial Results for the Third Quarter 2024 on Thursday, November 7, 2024, After Close of U.S.-Based Financial Markets

NKTR

PR Newswire

a year ago

Nektar to Announce Financial Results for the Third Quarter 2024 on Thursday, November 7, 2024, After Close of U.S.-Based Financial Markets

Nektar Announces Publication in Nature Communications of Results from Phase 1b Studies of Rezpegaldesleukin in Two Inflammatory Skin Diseases

NKTR

PR Newswire

a year ago

Nektar Announces Publication in Nature Communications of Results from Phase 1b Studies of Rezpegaldesleukin in Two Inflammatory Skin Diseases

NKTR

MT Newswires

a year ago

Nektar Therapeutics Up After Leukemia Candidate Found Beneficial in Early-Stage Study

NKTR

PR Newswire

a year ago

Nektar Announces Publication in Blood of Phase 1 Data for Novel IL-15 Agonist NKTR-255 in Combination with Autologous CD19-22 CAR-T Cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia

Nektar Therapeutics Announces Multiple Presentations for Rezpegaldesleukin at EADV 2024

NKTR

PR Newswire

a year ago

Nektar Therapeutics Announces Multiple Presentations for Rezpegaldesleukin at EADV 2024

Why Is Esperion Therapeutics (ESPR) Down 3.9% Since Last Earnings Report?

NKTR

Zacks

a year ago

Why Is Esperion Therapeutics (ESPR) Down 3.9% Since Last Earnings Report?

Nektar Management to Present at Upcoming Investor Conferences

NKTR

PR Newswire

a year ago

Nektar Management to Present at Upcoming Investor Conferences

NKTR

Zacks

a year ago

What Makes Nektar (NKTR) a New Buy Stock

Nektar Therapeutics Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

NKTR

Simply Wall St.

a year ago

Nektar Therapeutics Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

NKTR

Zacks

a year ago

Nektar's (NKTR) Q2 Earnings Lag Estimates, Revenues Top

NKTR

Zacks

a year ago

Latest Nektar Therapeutics (NKTR) News on October 8, 2025

Share on Social Networks: